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Abstract: BACKGROUND Renal graft thrombosis (RGT) is one of the main causes for early graft
loss in pediatric kidney transplantation (KTx). Despite the lack of evidence-based recommendations,
antithrombotic prophylaxis (aP) is used to prevent RGT. METHODS An online survey supported by
the European Society for Pediatric Nephrology was developed to investigate the current practice of aP
in pediatric KTx recipients <18 years. RESULTS A total of 80 pediatric KTx centers from 37 countries
participated in the survey. Antithrombotic prophylaxis was performed in 96% of the pediatric renal
transplant centers (all/selected patients: 54%/42%). The main overall used drugs were as follows: low-
molecular-weight heparin (89%), unfractionated heparin (UFH) (69%), and acetylsalicylic acid (ASS)
(55%). Ten different aP management strategies were identified as follows: 51% used a single drug and
48% combined two drugs sequentially. The corresponding centers started aP predominantly within 24
hours after pediatric KTx; 51% preferred UFH for starting aP. In centers switching to a second drug
(51%), this change was performed after 10 ± 6 days; of these 57% preferred ASS for maintenance aP.
Reported median aP duration was 51 days (range 1-360). CONCLUSIONS Despite the use of aP in
almost all responding pediatric KTx centers, there is no uniform management strategy. Notwithstanding,
UFH seems to be the preferred drug for the early post-operative period of pediatric KTx, and ASS for
maintenance prophylaxis following pediatric KTx. Prospective studies are needed to further evaluate the
benefits and risks of aP, preferably resulting in guidelines for the management in pediatric KTx.
DOI: https://doi.org/10.1111/petr.13799
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Background: Renal graft thrombosis (RGT) is one of the main causes for early graft 
loss	in	pediatric	kidney	transplantation	(KTx).	Despite	the	lack	of	evidence-based	rec-
ommendations,	antithrombotic	prophylaxis	(aP)	is	used	to	prevent	RGT.






follows:	 low-molecular-weight	 heparin	 (89%),	 unfractionated	 heparin	 (UFH)	 (69%),	
and	acetylsalicylic	 acid	 (ASS)	 (55%).	Ten	different	aP	management	 strategies	were	
identified	as	follows:	51%	used	a	single	drug	and	48%	combined	two	drugs	sequen-
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1  | INTRODUC TION
Renal transplantation is the treatment of choice for children and 
adolescents	 with	 end-stage	 renal	 disease.1 Although transplant 
survival	 rates	 have	 markedly	 improved	 over	 the	 last	 decades,	
renal graft thrombosis (RGT) remains a significant cause of early 
graft	 loss	 in	 pediatric	 kidney	 transplantation	 (KTx).2 Renal graft 
thrombosis	 occurs	 mostly	 within	 the	 first	 week	 following	 KTx.3 
The	 reported	 incidence	 of	 RGT	 varies	 between	 2.3%	 and	 5.1%,	
mainly	due	to	differences	in	study	populations	and	associated	risk	
factors.2,4	 The	 available	 evidence	 does	 not	 allow	 a	 quantitative	
differentiation of RGT into arterial or venous thromboses.5,6 The 
risk	 for	 developing	 a	 thrombotic	 episode	 due	 to	modifiable	 and	
non-modifiable	risk	factors	seems	to	be	higher	in	pediatric	than	in	
adult renal transplantation.7-9	Hence,	antithrombotic	prophylaxis	
(aP) with anticoagulants and antiplatelets is widely used to prevent 
RGT	in	pediatric	KTx.10-13	To	date,	an	evidence-based	management	




rent practice of aP management strategies in children and adoles-
cents <18	years	undergoing	KTx.
2  | MATERIAL S AND METHODS
2.1 | Study design
The	 electronic,	 questionnaire-based	 survey	 (SurveyMonkey	
Inc,	 www.surve	ymonk	ey.com)	 was	 developed	 in	 accordance	
with given recommendations on behalf of the “Transplantation 
Working	Group”	of	the	European	Society	for	Pediatric	Nephrology	
(ESPN).17
The	 questionnaire	 was	 structured	 into	 four	 sections	 with	 38	
items	 (open	 and	 multiple-choice	 questions):	 (a)	 demographic	 in-
formation about the responding center; (b) general characteris-
tics	 about	 the	 transplant	 center;	 (c)	 detailed	 questions	 addressing	
screening for thrombophilia during pretransplant evaluation; and (d) 
comprehensive information about aP including type of anticoagu-
lants	and	antiplatelets,	timing,	dosage,	mode	of	application,	monitor-
ing,	and	selection	criteria	of	aP	(Supporting	Information	S1).
The	 questionnaire	 was	 tested	 in	 advance	 by	 three	 physicians	
for	 the	 following	aspects:	 clarity,	utility,	and	 redundancy.	Changes	
were conducted following the suggestions. The adapted survey was 
finally tested by another five physicians.





because the study neither involved patients directly nor was any 
specific	patient	data	required.




ble (n = 17) and triple data entries (n =	3),	85	responding	pediatric	
nephrology centers were identified. Responders who did not per-
form renal transplantation in the pediatric population <18	 years	
(n = 4) or could not be assigned to a particular institution (n = 1) were 
excluded	 from	 the	analysis.	Finally,	80	pediatric	KTx	centers	were	
included for data evaluation.
2.3 | Statistical analyses
The	responses	were	collected	in	an	electronic	database	and	checked	
before the final analysis. Double and triple responses from one 
center were combined into a single answer. The overall completion 
rate	of	the	questions	within	the	entire	survey	was	84%	(67/80)	ex-
cluding	two	mandatory	questions	(Q24	and	Q30)	both	completed	by	
<50%	of	 the	 responders.	 The	 statistical	 analyses	were	 conducted	
and	reported	based	on	the	number	of	total	answers	for	each	ques-




Data	 were	 analyzed	 using	 the	 statistical	 package	 SPSS	 for	
Windows,	 release	21	 (IBM	Corp.).	Differences	between	subgroups	
were	calculated	using	the	Mann-Whitney	U test for continuous vari-
ables,	 and	P <	 .05	was	 considered	 significant.	Data	were	 checked	
for	normal	distribution	according	to	the	Kolmogorov-Smirnov	test.	





3.1 | General information about the participating 
centers
3.1.1 | Demographic and institutional 
characteristics




ported as follows: <5:24%	 (19/80);	 5-10:49%	 (39/80);	 11-20:20%	
(16/80),	and	>20:8%	(6/80).	In	71%	(57/80)	of	all	centers,	the	trans-
plant	procedure	was	carried	out	by	a	surgeon	specialized	in	pediatric	
transplantation.	 Ninety-nine	 percent	 (79/80)	 targeted	 a	 minimum	
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required	 body	weight	 of	 the	 recipient	 as	 follows:	 3	 to	<7	 kg:	 1%	
(1/79);	7-10	kg:	32%	(25/79);	and	>10	kg:	67%	(53/79).	Grafts	from	
donors with a body weight <5	kg	were	accepted	by	25%	(20/80)	of	
the survey responders.
3.2 | Preparation for pediatric kidney 
transplantation
3.2.1 | Screening for thrombophilia
Screening	 for	 thrombophilia	 was	 performed	 in	 94%	 (75/80)	 of	 all	
transplant	centers	with	55%	(44/80)	in	all	transplant	candidates	and	
39%	 (31/80)	 in	 a	 selected	 population	 only.	 Positive	 family	 history	
and	 previous	 thromboembolic	 complications	 (both	 97%	 [30/31])	
were the main reasons for selective screening (Table 1). An overview 
including all thrombophilia screening parameters is displayed in 
Table 2.
3.3 | Antithrombotic management
3.3.1 | General aspects of antithrombotic 
prophylaxis
A	protocol	 for	 aP	was	 available	 in	81%	 (60/74)	of	 all	 participating	
centers.	 A	 stratified	 risk	 assessment	 for	 aP	was	 reported	 by	 70%	
(52/74).	 Ninety-six	 percent	 (76/79)	 of	 the	 corresponding	 cent-
ers	performed	aP.	 In	54%	(43/79)	of	all	centers,	aP	was	used	in	all	
renal	transplant	patients.	In	the	remaining	centers	(42%	[33/79]),	aP	
was limited to a selected recipient population with specific reasons 
(Table 3; reasons only specified by 31 responders).
F I G U R E  1   Geographic location 
of	participating	centers	(N	=	80).	
Abbreviations:	n,	number
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3.3.2 | Anticoagulants and antiplatelets
Low-molecular-weight	heparin	(LMWH)	(89%	[66/74])	and	unfrac-




A	 total	 of	 10	 different	 center-specific	 standard	 strategies	 for	 aP	
were	identified	(Figure	3A).	A	single	drug	was	used	in	48%	(33/69)	
of	all	 responding	centers,	 and	a	change	 to	another	antithrombotic	




simultaneous use of drugs for aP was considered under specific cir-
cumstances	(Supporting	Information	S5).
UFH	 intravenously	or	 subcutaneously	was	administered	at	pe-
diatric	KTx	 in	51%	 (35/68)	 of	 the	 transplant	 centers	 as	 initial	 pro-
phylaxis	(Figure	3	B).	For	centers	changing	to	another	maintenance	
antithrombotic	drug	 (51%	 [35/68]),	 the	 favored	drug	was	oral	ASS	
(57%	[20/35])	(Figure	3C).
TA B L E  1   Reasons for thrombophilia screening in selected 
patients	(N	=	31)
Reasons n % of total
Positive family history for thromboembolic 
events
30 97
Previous thromboembolic complications 30 97
Re-kidney	transplantation 8 26




0 to <	6	years 1 3




aOther reasons: congenital nephrotic syndrome; concomitant oral 
contraception; clinical suspicion of thrombophilia; underlying condition 
such as systemic lupus erythematosus; age <4 years of age. 
TA B L E  2  Thrombophilia	screening	parameters	(N	=	74)





Platelet count 73 99















aOther screening parameters: activated protein C resistance; in case 
of	factor	V	Leiden	or	prothrombin	mutation:	plasminogen	activator	
inhibitor-1	polymorphism;	in	case	of	increased	homocysteine	level:	
genetic testing for mutations in the methylenetetrahydrofolate 
reductase gene; in special conditions (not specified): closing time/ 
thrombocyte aggregation (measured with adenosine triphosphate or 
epinephrine); in special conditions (not specified): platelet factor assay. 
TA B L E  3  Reasons	for	antithrombotic	prophylaxis	in	selected	
patients	(N	=	31)
Parameters n % of total
Previous thromboembolic complications of 
the patients
27 87
Positive thrombophilia screening 27 87




Arterial or venous anomalies 17 55
Large	donor	graft	to	small	recipient 14 45
Small	donor	graft	to	large	recipient 13 42




0 to <	6	years 9 29










recipients with a body weight <30	kg;	recipients	with	polyuria;	
congenital thrombophilia; prothrombotic immunological disease; 
history of thrombosis of at least 2 vessels; recipients receiving already 
prophylactic or therapeutic anticoagulant therapy; intraoperative 
complications	with	high	risk	of	thrombosis	(n	=	2);	kidney	transplant	
surgeon-	and/or	multi-professional	decisions	(n	= 2). 
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3.3.4 | Timing of aP
Antithrombotic	 prophylaxis	 was	 started	 preoperatively	 in	 11%	
(8/74),	 intra-operatively	 in	 22%	 (16/74),	within	12	hours	 in	 50%	
(37/74),	between	12	and	24	hours	in	14%	(10/74),	and	more	than	
24	 hours	 after	 pediatric	 KTx	 in	 4%	 (3/74)	 of	 the	 corresponding	
centers.
The	 time-point	 for	 changing	 the	 drug	 to	 maintenance	 pro-
phylaxis	 in	 centers	 using	 two	 drugs	 sequentially	 was	 on	 average	
10 ±	6	days	following	pediatric	KTx	(29/35;	6	centers	did	not	specify	
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the	time-point).	Antithrombotic	prophylaxis	was	discontinued	after	
a	median	 of	 51	 days	 (range	 1-360)	 after	 pediatric	 KTx	 (48/69;	 21	
centers	did	not	 report)	 (Figure	4).	Reported	criteria	 for	an	 individ-
ual point of time to maintenance antithrombotic regimen are shown 
in	Supporting	Information	S6	and	for	discontinuation	in	Supporting	
Information	 S7.	 ASS-based	 aP	 strategies	 were	 conducted	 signifi-
cantly	longer	than	UFH-	or	LMWH-based	strategies	(127	± 111 days 
vs	52	±	78	days,	respectively;	P < .001). Detailed information for aP 
duration is provided in Table 4.
3.3.5 | Dosing and therapeutic drug monitoring





This survey clearly demonstrates that the vast majority of the par-
ticipating	pediatric	renal	transplant	centers	favor	aP	in	pediatric	KTx	
even though studies show conflicting results toward the beneficial 
effects for prevention of RGT.11,15,18
While	a	significant	number	of	renal	transplant	centers	perform	
aP	 in	all	 renal	 transplant	patients,	other	transplant	centers	restrict	
aP	to	selected	patients	with	a	suggested	distinct	higher	risk	for	de-
veloping RGT.4,9,13,15	 Interestingly,	 criteria	 for	 assignment	 of	 renal	
transplant	candidates	 to	 the	high-risk	group	for	RGT	differ	among	









a minority of reporting centers do not use aP at all which might be 
supported by the findings of a few studies.9,11,20
Most	 pediatric	 renal	 transplant	 patients	 develop	RGT	within	 a	
few	 hours	 post-transplant.3,21	Hence,	 it	 is	 not	 remarkable	 that	 al-
most	 all	 renal	 transplant	 centers	 initiate	 aP	 in	 the	 peri-	 or	 early	
post-operative	phase	following	surgical	intervention.	The	timing	of	
the management strategy for aP reflects study protocols of previ-
ous published studies.10,22 In contrast to the comparatively uniform 
starting	 time-point	 of	 aP	 at	 pediatric	 KTx,	 the	 overall	 duration	 of	
aP varies significantly among the participating centers. Renal graft 
thrombosis	most	frequently	occurs	within	the	first	month	after	KTx,	
with	a	peak	in	the	first	week	post-transplant.3,21	Therefore,	it	is	even	
the more astonishing that a few transplant centers prolong the aP to 
more than three months which does not correspond to other stud-
ies.5,10,11	 Nevertheless,	 the	 prolonged	 use	 of	 aP	 is	 astonishing	 as	
both early and late thromboses are more often related to numerous 
other	factors	such	as	hyperacute	rejection	by	preformed	antibodies,	
surgical	experience	 regarding	vessel	 anastomoses,	 small	 vessels	 in	
either	the	donor	graft	or	the	recipient,	which	are	not	associated	with	
coagulation disorders and therefore cannot be modified by anticoag-
ulants and antiplatelets.23	Within	this	context,	a	limited	use	of	aP	for	
only	a	few	days	or	weeks	following	pediatric	KTx	could	be	discussed.	
In centers practicing a management strategy with a change to an-
other	 maintenance	 antithrombotic	 drug,	 most	 centers	 switchover	
within	one	to	two	weeks	following	pediatric	KTx.9,24	We	assume	that	
the selection of this time period correlates positively with the clini-
cal	improvement	of	the	renal	transplant	patient,	the	associated	renal	
transplant	function,	and	lastly	with	the	discharge	from	the	hospital.
The considerable high multitude of antithrombotic management 
strategies represents uncertainty to the best practice which might 
arise from the limited evidence from few predominantly retrospec-
tive	studies	with	small	sample	sizes.10-12,15	In	addition,	there	is	only	
moderate	to	low	quality	evidence	that	anticoagulants	are	superior	
in prevention of venous thromboses and antiplatelets in arterial 
thromboses.25,26	 Notwithstanding,	 the	 favored	 antithrombotic	
drug is heparin in accordance with published studies in pediatric 







F I G U R E  4   Discontinuation of 
antithrombotic	prophylaxis.	Abbreviations:	
KTx,	kidney	transplantation;	n,	number
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venous	 lines	 and	 the	 assigned	 lower	 associated	 costs	 of	UFH.9,27 
Notwithstanding,	 LMWH	 subcutaneously	 is	 the	most	 often	 used	
overall	 antithrombotic	 drug,	 followed	 by	 UFH	 intravenously	 and	
oral	ASS.10-12,21
It remains uncertain if anticoagulation with heparin or antiplate-










though	 the	 alteration	 from	 heparin	 to	 oral	 ASS	 adds	 up	 from	 the	
clinical	point	of	view,	 there	 is	only	one	study	showing	a	beneficial	
effect.28 The evidence for combination of different drugs for aP is 
scarce and inconclusive.15	Therefore,	it	is	not	a	surprise	that	the	si-
multaneous use of two drugs for aP was reported only as an alterna-
tive option for specific individual patients.
Interestingly,	 the	 information	 about	 dosing	 of	 the	 single	 drugs	
for aP was not only very limited due to an insufficient response rate 
but also highly heterogeneous which precludes a conclusive anal-
ysis.	This	 finding	 is	 somewhat	unclear	as	 there	are	existing	dosing	
recommendations and available blood parameters to monitor the 
effects of aP.29,30	In	addition,	drug	monitoring	for	aP	was	part	of	the	
management strategy in only slightly more than half of the trans-
plant centers which is an inscrutable finding because thereby a criti-
cal	evaluation	of	a	dose-response	correlation	is	not	possible.31	With	
respect	to	a	critical	evaluation	of	the	risk-benefit	balance	of	aP,	drug	
monitoring	making	 it	all	 the	more	 important	as	 there	are	only	 few	




often used monitoring parameter for aP are partial thromboplastin 
time	and	anti-Xa-activity.33
Though thrombophilia screening in children prior to pediatric 
KTx	is	a	matter	of	debate	due	to	conflicting	results	and	limited	data,	
most transplant centers perform thrombophilia screening per proto-
col as standard of care in renal transplant patients.9,34 The parame-
ters of routine investigation for thrombophilia differ hardly among 
the different transplant centers corresponding to common recom-
mendations.34,35	Within	 this	 context,	 screening	 for	known	genetic	
causes	 of	 thrombophilia	 including	 factor	 V	 Leiden	mutation,	 pro-
thrombin	mutation,	 or	methylenetetrahydrofolate	 reductase	 poly-
morphism	was	performed	by	54	 to	78%	of	 the	 transplant	 centers	
prior	to	pediatric	KTx.35	Interestingly,	while	screening	for	thrombotic	
risk	 factors	 is	done	 in	all	 renal	 transplant	candidates	 in	more	 than	
half	of	the	transplant	centers,	about	one	third	of	all	transplant	cen-
ters restrict thrombophilia screening to a selected population with 
an	estimated	higher	hazard	of	developing	RGT.34	Albeit	the	risk	fac-
tors	attributed	for	increasing	the	likelihood	of	RGT	are	diverse,	pos-
itive	 family	 history,	 previous	 events	 of	 thromboembolic	 episodes,	
and	re-transplantations	appear	to	be	the	main	determining	factors	
in the pediatric transplant centers similar to data from adult renal 
transplantation.36	Surprisingly,	the	selected	thrombophilia	screening	
does not necessarily result in a tailored aP for the patients with pos-
itive	thrombophilia	markers.	About	one	third	of	centers	perform	aP	








Mean ± SD, d Median, d R, d n n
UFH	iv 25	± 30 18 1-90 7 3
UFH	iv	+	UFH	s.c. 9 — — 1 0
UFH	iv	+	LMWH	s.c. 88	± 111 28 12-360 9 5
UFH	iv	+	ASS	p.o. 237 ±	135 270 60-360 5 2
UFH	s.c. 16	± 20 16 2-30 2 1
LMWH	iv	+	ASS	p.o. 75	± 21 75 60-90 2 0
LMWH	s.c. 60	±	76 17 4-180 9 4
LMWH	s.c.	+	ASS	p.o. 107 ± 99 87 30-360 10 1







TA B L E  4   Duration of antithrombotic 
prophylaxis	strategies	(N	=	48)
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compared	 to	 previous	 published	 ESPN-based	 surveys	 focusing	
on	 aspects	 of	 pediatric	 KTx,	 the	 number	 of	 responses	was	 rather	
above-average.37,38	 Second,	 though	 a	 homogenous	 distribution	 of	
the	responding	pediatric	KTx	centers	all-over	Europe	endorses	the	
representative value for the investigation of the current practice of 
aP,	only	a	minority	of	pediatric	KTx	centers	outside	Europe	partici-
pated	in	the	survey.	Consequently,	the	findings	might	not	reflect	the	
management strategies in other underrepresented transplant cen-
ters,	particularly	 in	Northern	America.	Otherwise,	the	reliability	of	
the reported data is corroborated by an available standard protocol 
for renal transplantation including the management of aP in almost 
all	participating	centers.	Therefore,	the	generalizability	of	the	find-
ings to a wider base of renal transplant centers might be assumed.
In	conclusion,	despite	the	use	of	aP	in	almost	all	responding	pe-




The heterogeneous results of this survey indicate that a harmo-
nization	 and	 standardization	of	 aP	management	 strategies	 in	 pe-
diatric renal transplant recipients is urgently needed. Prior to the 
development	of	consensus	 recommendations,	 for	 instance	by	se-
lecting	the	Delphi	survey	method,	more	data	on	aP	in	pediatric	KTx	
should	 be	 generated.	Within	 this	 context,	 a	 complementary	 sys-
tematic review could be helpful to collate all the available current 
information and to elucidate important criteria for further studies. 
These	 studies,	 preferably	 prospective	 randomized	 controlled	 tri-
als,	are	essential	to	further	evaluate	the	benefits	and	risks	of	aP	in	
pediatric	KTx.
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Argentina);	 Kibriya	 Fidan	 (Department	 of	 Pediatric	 Nephrology,	
Gazi	University	Medical	School,	Gazi,	Turkey);	Marc	Fila	(Pediatric	
Nephrology—CHU	Arnaud	de	Vielleneuve,	Montpellier	University	
Hospital,	 France);	 Michaela	 Gessner	 (Department	 of	 General	
Pediatrics	 and	 Hematology/Oncology,	 University	 Children`s	
Hospital,	 University	 Hospital	 Tübingen,	 Tübingen,	 Germany);	
Ryszard	Grenda	(The	Children's	Memorial	Health	Institute,	Warsaw,	





Karolinska	 University	 Hospital,	 Stockholm,	 Sweden);	 Nakysa	
Hooman	 (Aliasghar	Children	Hospital,	 Aliasghar	Clinical	 Research	
Development	Center,	Iran	University	of	Medical	Sciences,	Tehran,	
Iran);	 Lilian	 Johnstone	 (Monash	 Children's	 Hospital,	 Melbourne,	
Australia);	Michael	 Kaabak	 (Organ	 transplant	 division	 in	National	
Medical	 Research	 Center	 for	 Children's	 Health,	 Boris	 Petrovsky	




Noel	 Knops	 (University	 Hospital	 Leuven,	 Leuven,	 Belgium);	 Jens	
Koenig	(University	Children`s	Hospital	Münster,	Germany);	Matjaz	
Kopac,	 (Children's	 Hospital	 Ljubljana,	 University	 Clinical	 Centre	
Ljubljana,	Ljubljana,	Slovenia);	Eda	Didem	Kurt-Şükür	(Department	
of	 Pediatric	 Nephrology,	 Ankara	 Dr	 Sami	 Ulus	 Maternity	 and	
Children	Hospital,	 Ankara,	 Turkey);	 Angela	 Lamb	 (Pediatric	 Renal	
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Unit,	 Royal	 Hospital	 for	 Children	 Glasgow,	 Glasgow,	 United	
Kingdom);	 Guido	 F.	 Laube	 (Pediatric	 Nephrology	 Department;	
University	 Children`s	 Hospital	 Zurich,	 Zurich,	 Switzerland);	
Mercedes	 Lopez	 (Vall	 d´Hebrón	 Hospital,	 Barcelona,	 Spain);	 Ma.	
Angeles	Marbella	(National	Kidney	and	Transplant	Institute,	Quezon	
City,	 Philippines);	 Jurate	 Masalskiene	 (Hospital	 of	 Lithuanian	
University	of	Health	Sciences,	Kaunas,	Lithuania);	Marta	Melgosa	
(Pediatric	 Nephrology,	 Hospital	 Universitario	 La	 Paz,	 Madrid,	




NHS	 Foundation	 Trust,	 Liverpool,	 United	 Kingdom);	 Conceição	
Mota	(Centro	Hospitalar	do	Porto,	Porto,	Portugal);	Dominik	Müller	
(Department	 of	 Pediatric	 Gastroenterology,	 Nephrology	 and	
Metabolic	 Diseases,	 Charité	 University	 Medicine	 Berlin,	 Berlin,	
Germany);	 Luisa	 Murer	 (Pediatric	 Nephrology,	 Dialysis	 and	
Transplantation	 Unit,	 Department	 of	 Women's	 and	 Children's	
Health,	University	Hospital	of	Padua,	Padua,	Italy);	Bogna	Niwińska-
Faryna	(Pediatric	Nephrology,	The	Children's	and	Women's	Health	
Theme,	 Karolinska	 University	 Hospital,	 Stockholm,	 Sweden);	
Robert	 Novo	 (University	 Hospital	 Lille,	 Lille,	 France);	 Lars	 Pape	
(Department	 of	 Pediatric	 Kidney,	 Liver	 and	 Metabolic	 Diseases,	
Hannover	 Medical	 School,	 Hannover,	 Germany);	 Licia	 Peruzzi	
(Regina	Margherita	Children's	Hospital,	Turino,	 Italy);	Martin	Pohl	
(Pediatric	 Nephrology	 Department,	 University	 Hospital	 Freiburg,	
Freiburg,	 Germany);	 Nikoleta	 Printza	 (Pediatric	 Nephrology	 Unit,	
First	 Pediatric	 Department,	 Hippokration	 General	 Hospital,	
Aristotle	 University,	 Thessaloniki,	 Greece);	 Agnieszka	 Prytula	
(Ghent	 University	 Hospital,	 Ghent,	 Belgium);	 Andreaa	 Rachisan	
(University	of	Medicine	and	Pharmacy	Cluj-Napoca,	Cluj-Napoca,	
Romania);	 George	 S.	 Reusz	 (First	 Department	 of	 Pediatrics,	
Semmelweis	 University;	 Budapest,	 Hungary);	 Ben	 Reynolds	
(Pediatric	Renal	Unit,	Royal	Hospital	for	Children	Glasgow,	Glasgow,	
United	 Kingdom);	 Pornpimol	 Rianthavorn	 (Faculty	 of	 Medicine,	
Chulalongkorn	 University,	 Bangkok,	 Thailand);	 Dimitar	 Roussinov	
(Pediatric	University	Hospital,	Medical	University,	Sofia,	Bulgaria);	
Rina	Rus	 (Children's	Hospital	 Ljubljana,	University	Clinical	Centre	
Ljubljana,	 Ljubljana,	 Slovenia);	Raphael-Sebastian	Schild	 (Pediatric	
Nephrology	Department,	University	Hospital	Hamburg	Eppendorf,	
Hamburg,	 Germany);	 Anne-Laure	 Sellier-Leclerc	 (Pediatric	




Royal	 Manchester	 Children's	 Hospital,	 Manchester,	 United	
Kingdom);	 Jasna	 Slaviček	 (Department	 for	 Pediatric	 Nephrology,	
Dialysis	and	Transplantation,	Department	of	Pediatrics,	University	
Hospital	 Centre	 Zagreb,	 University	 of	 Zagreb	 Medical	 School,	
Zagreb,	 Croatia);	 Stella	 Stabouli	 (Pediatric	Nephrology	Unit,	 First	
Pediatric	 Department,	 Hippokration	 General	 Hospital,	 Aristotle	
University,	 Thessaloniki,	 Greece);	 Julie	 Tenenbaum	 (Pediatric	
Nephrology—CHU	Arnaud	de	Vielleneuve,	Montpellier	University	
Hospital,	 France);	 Sara	 Testa	 (Pediatric	 Nephrology,	 Dialysis	 and	
Transplantation	 Unit,	 Fondazione	 IRCCS	 Ca'	 Granda	 Ospedale	
Maggiore	 Policlinico,	 Milan,	 Italy);	 Rezan	 Topaloğlu	 (Division	 of	
Pediatric	 Nephrology,	 Hacettepe	University	 Faculty	 of	Medicine,	
Ankara,	 Turkey);	 Peter	 Trnka	 (Children's	 Health	 Queensland,	
Brisbane,	 Australia);	 Sibylle	 Tschumi	 (Division	 of	 Pediatric	
Nephrology,	 Children's	 Hospital,	 University	 of	 Bern,	 Bern,	
Switzerland);	 Yincent	 Tse	 (Department	 of	 Pediatric	 Nephrology,	
Great	 North	 Children's	 Hospital,	 Newcastle	 upon	 Tyne,	 United	
Kingdom);	Siegfried	Waldegger	(Department	of	Pediatrics	I,	Medical	






Nephrology,	 Department	 of	 Pediatrics,	 Pamukkale	 University	
Faculty	 of	Medicine,	Denizli,	 Turkey);	 Jakub	 Zieg	 (Department	 of	
Pediatrics,	Second	Faculty	of	Medicine,	Charles	University	Prague,	
University	 Hospital	 Motol,	 Prague,	 Czech	 Republic);	 further	 re-
sponses were retrieved from the following institutions (correspond-
ing	 physicians	 unknown):	 Children's	 Hospital	 P.	 and	 A.	 Kyriakou,	
University	of	Athens	School	of	Medicine,	Greece;	Royal	Hospital,	
Muscat,	 Oman;	 Shaare	 Zedek	 Medical	 Center,	 Jerusalem,	 Israel;	
and	Medical	University	of	Vienna,	Austria.
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